The federal Project Grant award of $1,247,028 to Cantata Bio LLC, awarded by the National Human Genome Research Institute (NHGRI) under the Human Genome Research (CFDA 93.172) program, supports the commercialization of Cantata Bio's "VariLink" technology - an innovative Hi-C workflow that enhances the detection of cancer-driving structural variants in the genome. The award will enable Cantata Bio to further develop and validate its rapid, automated Hi-C platform for sensitive genomic profiling of multiple cancer sample types. This aligns with the NHGRI's mission to support the development of resources and technologies that accelerate genome research and its application to human health and genomic medicine.
Generated 1/28/25, 7:23 AM